Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18884680 | BACTERIAL COMPOSITIONS FOR TREATING AND PREVENTING HALITOSIS | September 2024 | November 2025 | Allow | 14 | 2 | 1 | No | No |
| 18627183 | PROBIOTIC COMPOSITIONS FOR TREATING AND PREVENTING COLORECTAL CANCER | April 2024 | February 2026 | Allow | 22 | 3 | 1 | Yes | No |
| 17909760 | BACILLUS VELEZENSIS STRAIN BRED THROUGH ULTRASOUND-ASSISTED ADAPTIVE EVOLUTION, AND USE THEREOF | February 2023 | January 2025 | Abandon | 28 | 0 | 1 | No | No |
| 18152641 | NOVEL STREPTOCOCCUS THERMOPHILUS STRAIN AND PROBIOTIC COMPOSITION AND USE THEREOF | January 2023 | June 2025 | Abandon | 29 | 3 | 1 | Yes | No |
| 18147722 | LACTOBACILLUS SAKEI AND METHOD FOR EYE PROTECTION WITH LACTOBACILLUS SAKEI OR METABOLITE THEREOF | December 2022 | May 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17927167 | COMPOSITION FOR TREATING RESPIRATORY DISEASES OR INFLAMMATORY DISEASES CAUSED BY FINE DUST STIMULATION, CONTAINING LACTIC ACID BACTERIA | November 2022 | March 2026 | Allow | 40 | 1 | 1 | Yes | No |
| 17985500 | LACTOBACILLUS SAKEI FOR ALLEVIATING ALLERGY AND PREPARATION METHOD THEREOF | November 2022 | February 2024 | Abandon | 15 | 1 | 1 | No | No |
| 17979878 | METHOD FOR PRODUCING MONOUNSATURATED FATTY ACID HAVING 16 CARBON ATOMS | November 2022 | March 2024 | Abandon | 16 | 0 | 1 | No | No |
| 17973449 | PROBIOTIC COMPOSITIONS FOR LONG COVID | October 2022 | August 2025 | Allow | 34 | 6 | 1 | Yes | No |
| 17969941 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE AND JOINT DISEASES | October 2022 | July 2024 | Abandon | 21 | 3 | 1 | No | No |
| 17968831 | SELECTIVE MEDIUM COMPOSITION FOR DETECTION OF P. CAROTOVORUM AND DETECTION METHOD USING THE SAME | October 2022 | September 2024 | Allow | 23 | 4 | 0 | Yes | No |
| 17968161 | SPORE-BASED PROBIOTIC COMPOSITION FOR REDUCTION OF DIETARY ENDOTOXEMIA AND RELATED METHODS | October 2022 | March 2026 | Abandon | 41 | 2 | 0 | No | No |
| 17996501 | COMPOSITION FOR PREVENTING OR TREATING LIPID-RELATED METABOLIC DISEASES, COMPRISING LACTOBACILLUS PLANTARUM ATG-K2 OR ATG-K6 | October 2022 | January 2026 | Abandon | 39 | 1 | 1 | No | No |
| 18045264 | USE OF DOPAMINE PRODUCING PRODUCTS TO INCREASE VACCINE EFFICACY | October 2022 | March 2025 | Allow | 29 | 4 | 1 | Yes | Yes |
| 17917385 | COMPOSITION FOR IMPROVING GUT MICROBIOTA | October 2022 | September 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17913505 | MICROORGANISM FOR IMPROVING LIVER FUNCTION OR INHIBITING FAT ACCUMULATION, AND USES OF SAME | September 2022 | August 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17949757 | COMPOSITION FOR PROPHYLAXIS OF ENTERITIS IN AVIAN COMPRISING LACTOBACILLUS PLANTARUM STRAIN | September 2022 | July 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17913210 | LACTOBACILLUS DELBRUECKII SUBSP. LACTIS CKDB001 STRAIN, AND COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER COMPRISING SAME | September 2022 | October 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17932427 | Isolated Strain Of Lactic Acid Bacteria For Inhibiting Drug-Resistant Enterobacteriaceae, Lactic Acid Bacterial Composition And Symbiotic Composition Including The Same | September 2022 | December 2024 | Abandon | 27 | 3 | 0 | No | No |
| 17909141 | LACTIC ACID BACTERIUM-CONTAINING COMPOSITION | September 2022 | July 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17895071 | PROBIOTICS SEPARATED FROM RABBIT FECES AND FOOD CONTAINING PROBIOTICS | August 2022 | January 2025 | Abandon | 29 | 3 | 0 | Yes | No |
| 17893840 | Novel Lactobacillus Fermentum LM1016 Strain, And Composition For Preventing Or Treating Cardiovascular Diseases | August 2022 | July 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17881498 | PROBIOTIC COMPOSITIONS FOR TREATING AND PREVENTING COLORECTAL CANCER | August 2022 | January 2024 | Allow | 17 | 3 | 1 | Yes | Yes |
| 17815447 | METHOD FOR PREPARING R-HYDROXYNITRILE LYASE AND USE THEREOF | July 2022 | November 2023 | Allow | 16 | 1 | 1 | Yes | No |
| 17866911 | METHODS FOR MANUFACTURING ANGELICA GIGAS NAKAI EXTRACT USING FERMENTATION BACTERIA | July 2022 | March 2024 | Abandon | 20 | 2 | 0 | No | No |
| 17792585 | Bacterium, Composition and Method for Producing Same, and Prebiotics Composition | July 2022 | March 2026 | Allow | 44 | 2 | 1 | Yes | No |
| 17792329 | METHODS FOR TREATING OR AMELIORATING AUTISM AND RELATED DISORDERS | July 2022 | January 2026 | Abandon | 43 | 1 | 1 | No | No |
| 17824452 | ATTENUATED SALMONELLA GALLINARUM MUTANT STRAINS AND USES THEREOF | May 2022 | November 2024 | Abandon | 30 | 4 | 0 | No | No |
| 17824608 | ATTENUATED SALMONELLA GALLINARUM MUTANT STRAINS AND USES THEREOF | May 2022 | November 2024 | Abandon | 30 | 4 | 0 | No | No |
| 17741951 | PROCESS FOR THE PREPARATION OF ANTIMALASSEZIA POWDER | May 2022 | November 2025 | Allow | 42 | 3 | 0 | Yes | No |
| 17726481 | VACCINATION AGAINST FUNGAL EPITOPES TO PREVENT INFLAMMATORY BOWEL DISEASES | April 2022 | April 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17657902 | BIOCONVERSION OF METHANE TO 3-HYDROXYBUTYRATE | April 2022 | March 2024 | Abandon | 23 | 2 | 0 | No | No |
| 17711430 | ENGINEERED CYCLIC GMP-AMP SYNTHASE (cGAS) VARIANT ENZYMES | April 2022 | August 2024 | Allow | 29 | 3 | 1 | Yes | No |
| 17691075 | CONVERSION OF LIGNIN-DERIVED MONOMERS TO MUCONATE BY ENGINEERED PSEUDOMONAS | March 2022 | March 2026 | Allow | 48 | 6 | 0 | Yes | No |
| 17635942 | THERAPEUTIC CONJUGATE | February 2022 | June 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17634074 | BACTERIAL COMPOSITIONS FOR THE TREATMENT OF DISEASE | February 2022 | June 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17575460 | RECOMBINANT MICROORGANISM HAVING HIGH ABILITY TO PRODUCE LUTEIN AND METHOD FOR PRODUCING LUTEIN USING THE SAME | January 2022 | January 2026 | Abandon | 48 | 6 | 1 | No | No |
| 17564567 | EDIBLE WEB COMPRISING MICROORGANISMS | December 2021 | November 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17551271 | OLEAGINOUS MICROBE SUPPLEMENTATION FOR IMPROVING BLACK SOLDIER FLY GROWTH AND DEVELOPMENT | December 2021 | July 2025 | Abandon | 43 | 5 | 1 | No | No |
| 17549692 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | December 2021 | February 2025 | Abandon | 39 | 4 | 1 | No | No |
| 17547845 | DIAGNOSING HEART DISEASE AND DEGENERATIVE MITRAL VALVE DISEASE IN A CANINE | December 2021 | November 2025 | Abandon | 47 | 5 | 1 | No | Yes |
| 17536412 | Pediococcus acidilactici CCFM6432 for Alleviating Depression, Food Fermented Thereby and Application Thereof | November 2021 | July 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17611240 | STRAIN SHOWING LIVER FUNCTION IMPROVING ACTIVITY, AND USE THEREOF | November 2021 | November 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17609975 | DEPOLYMERASE CAPABLE OF DEGRADING EXTRACELLULAR POLYMERIC SUBSTANCES OF KLEBSIELLA PNEUMONIAE | November 2021 | June 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17519595 | PREBIOTIC COMPOSITION AND METHOD FOR IMPROVING INTESTINAL HEALTH USING THE SAME | November 2021 | May 2025 | Allow | 42 | 6 | 0 | Yes | No |
| 17520561 | MESH-BASED IN SITU CROSS-LINKABLE COMPOSITIONS | November 2021 | February 2026 | Abandon | 51 | 3 | 0 | Yes | No |
| 17608729 | NOVEL HYALURONIDASE VARIANTS WITH IMPROVED STABILITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | November 2021 | December 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17492367 | PREDICTING SKIN AGE BASED ON THE ANALYSIS OF SKIN FLORA AND LIFESTYLE DATA | October 2021 | December 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17600650 | NOVEL BIFIDOBACTERIUM LONGUM STRAIN OR COSMETIC COMPOSITION COMPRISING SAME | October 2021 | November 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17600461 | ELASTASE ACTIVITY INHIBITOR, ELASTASE ACTIVITY INHIBITING TOPICAL AGENT, AND ELASTASE ACTIVITY INHIBITING FOOD AND BEVERAGE COMPOSITION | September 2021 | January 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17599104 | BACILLUS COAGULANS AND BACILLUS SUBTILIS FOR THE PREVENTION AND TREATMENT OF FUNCTIONAL GASTRO-INTESTINAL DISORDERS | September 2021 | June 2025 | Allow | 44 | 2 | 1 | No | No |
| 17436021 | COMBINATIONS OF TANNASE AND PROBIOTIC FORMULATIONS AND METHODS OF USE FOR IMPROVING TANNIN METABOLISM | September 2021 | February 2026 | Abandon | 53 | 2 | 1 | No | No |
| 17432846 | BACTERIAL MEMBRANE PREPARATIONS | August 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17432225 | COMPOSITIONS AND METHODS OF MODULATING CASOTRANSMITTER SIGNALING | August 2021 | January 2026 | Abandon | 53 | 3 | 1 | No | No |
| 17431040 | Hemostatic Enzyme and Carboxymethyl Chitosan-Containing Composition for Blood Coagulation Test, and Use Thereof | August 2021 | February 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17392975 | METHODS AND COMPOUNDS FOR NATURAL ORGANIC INTENSIVE SKIN REPAIR AND HEALING | August 2021 | September 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17425080 | METHODS AND COMPOSITIONS FOR TREATING INTESTINAL DISORDER | July 2021 | August 2025 | Allow | 49 | 4 | 1 | Yes | No |
| 17379605 | METHODS FOR CHROMATOGRAPHIC PROTEIN EXTRACTION AND PURIFICATION | July 2021 | December 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17422719 | METHODS AND COMPOSITIONS FOR TREATING IMMUNE CHECKPOINT INHIBITOR ASSOCIATED COLITIS | July 2021 | January 2026 | Abandon | 54 | 4 | 1 | Yes | No |
| 17360695 | METHODS FOR IDENTIFYING TARGETS FOR ANTIMICROBIAL AND ANTIPROLIFERATIVE COMPOUNDS AND COMPOSITIONS THEREFROM | June 2021 | November 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17279247 | AKKERMANSIA MUCINIPHILA STRAIN AND USE THEREOF | March 2021 | August 2025 | Allow | 52 | 3 | 1 | Yes | No |
| 17276334 | IMMUNE CHECKPOINT SUPPRESSANT | March 2021 | March 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17181884 | RECOMBINANT TRANSMEMBRANE DOMAIN-DEFICIENT STING AS BIOMIMETIC PROTEIN CARRIER FOR CGAMP ENHANCED CANCER IMMUNOTHERAPY | February 2021 | March 2024 | Abandon | 37 | 0 | 2 | No | No |
| 17166515 | METHOD FOR PRODUCING STABLE ACTINIDIA DELICIOSA POWDER WITH HIGH LEVEL BIOACTIVE ACTINIDIN ENZYME | February 2021 | August 2024 | Allow | 42 | 3 | 1 | Yes | No |
| 17264722 | FLUORESCENT-LABELED ANTIBODY OR ANTIBODY FRAGMENT | January 2021 | July 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17258297 | SELF-ASSEMBLING PEPTIDE SCAFFOLD | January 2021 | July 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 17254206 | COMPOSITION FOR IMPROVING LIVER FUNCTION COMPRISING LEUCONOSTOC SP. STRAIN | December 2020 | January 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17115591 | PLAP-CAR-EFFECTOR CELLS | December 2020 | February 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 16972741 | Engineering Extracellular Vesicles for Affinity Purification | December 2020 | June 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17056569 | RECOMBINANT BOVINE FOLLICLE-STIMULATING HORMONE, COMPOSITION COMPRISING THE SAME, AND METHOD TO INDUCE SUPEROVULATION AND ESTRUS SYNCHRONIZATION IN BOVINES USING SAID HORMONE | November 2020 | October 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17054089 | METHOD FOR MEASURING AND IMPROVING GUT HEALTH | November 2020 | August 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17050639 | MODIFIED STEROL ACYLTRANSFERASES | October 2020 | January 2026 | Allow | 60 | 4 | 1 | Yes | No |
| 17049756 | METHOD FOR PRODUCING COENZYME Q10 | October 2020 | April 2025 | Abandon | 53 | 2 | 0 | No | No |
| 17048916 | COMPOSITION FOR TYPE I ALLERGY | October 2020 | December 2023 | Abandon | 38 | 1 | 0 | No | No |
| 17048355 | Variant Asparaginase Polypeptides for Medical Use | October 2020 | January 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17060503 | BREATH TEST DEVICE AND METHOD | October 2020 | July 2024 | Abandon | 46 | 2 | 0 | No | No |
| 17042984 | METHODS OF PURIFYING MONOMERIC MONOCLONAL ANTIBODIES | September 2020 | November 2025 | Abandon | 60 | 4 | 0 | No | No |
| 17019422 | HARVESTING SYSTEMS AND METHODS FOR REMOVAL OF ALGAE SLURRY IMPURITIES | September 2020 | October 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16980364 | Magnetic Nanoparticles for use in Assisted Reproduction | September 2020 | September 2024 | Abandon | 48 | 1 | 1 | No | No |
| 17010644 | Enhanced adoptive cell therapy | September 2020 | May 2025 | Allow | 57 | 3 | 0 | No | No |
| 16965743 | METHOD FOR EFFICIENTLY RECOVERING AND PURIFYING ACTIVE CRM197 FROM INSOLUBLE CRM197 PROTEIN EXPRESSED IN INCLUSION BODY | July 2020 | March 2025 | Abandon | 55 | 3 | 0 | No | No |
| 16962793 | MANUFACTURE OF GLUCAGON PEPTIDES | July 2020 | November 2025 | Allow | 60 | 3 | 1 | No | No |
| 16771772 | AMINOPEPTIDASE AND ITS USES | June 2020 | December 2024 | Abandon | 54 | 3 | 1 | No | No |
| 16766977 | A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS | May 2020 | January 2024 | Abandon | 44 | 2 | 0 | No | No |
| 16760377 | NOVEL RECOMBINANT BOTULINUM TOXIN WITH INCREASED DURATION OF EFFECT | April 2020 | October 2024 | Abandon | 54 | 4 | 1 | Yes | No |
| 16755129 | ELASTIN REDUCTION ALLOWING RECELLULARIZATION OF CARTILAGE IMPLANTS | April 2020 | July 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16632060 | MANUAL METHOD FOR DEPOSITING A SAMPLE DIRECTLY ONTO A SLIDE FOR LIQUID BASED CYTOLOGY | January 2020 | August 2024 | Allow | 55 | 4 | 0 | Yes | Yes |
| 16609146 | METHOD AND DEVICE FOR PROVIDING A CELL LINE HAVING A DESIRED TARGET PROTEIN EXPRESSION | October 2019 | December 2023 | Abandon | 50 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CRUM, MARY ABOU NADER.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CRUM, MARY ABOU NADER works in Art Unit 1657 and has examined 51 patent applications in our dataset. With an allowance rate of 27.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner CRUM, MARY ABOU NADER's allowance rate of 27.5% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CRUM, MARY ABOU NADER receive 2.16 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CRUM, MARY ABOU NADER is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +70.5% benefit to allowance rate for applications examined by CRUM, MARY ABOU NADER. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.8% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 15.8% of cases where such amendments are filed. This entry rate is in the 17% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 57.1% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.